Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IPH4502 |
| Synonyms | |
| Therapy Description |
IPH4502 is an antibody-drug conjugate (ADC) targeting comprising a monoclonal antibody targeting Nectin4 linked to exatecan, which potentially induces killing Nectin4-expressing tumor cells and antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 5443). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IPH4502 | IPH-4502|IPH 4502 | NECTIN4 Antibody 11 | IPH4502 is an antibody-drug conjugate (ADC) targeting comprising a monoclonal antibody targeting Nectin4 linked to exatecan, which potentially induces killing Nectin4-expressing tumor cells and antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 5443). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06781983 | Phase I | IPH4502 | Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |